CORRECTION

Correction to: Efficacy, Safety, and Exposure of Apixaban in Patients with High Body Weight or Obesity and Venous Thromboembolism: Insights from AMPLIFY

Alexander T. Cohen · Sharon Pan · Wonkyung Byon ·
Bushra S. Ilyas · Thomas Taylor · Theodore C. Lee

© Crown 2021

Correction to: Adv Ther
<https://doi.org/10.1007/s12325-021-01716-8>

In the original article, Figure 1 was published incorrectly. The correct Fig. 1 is given below.

The original article can be found online at <https://doi.org/10.1007/s12325-021-01716-8>.

A. T. Cohen (✉) · T. Taylor
Guy's and St Thomas' Hospitals, Westminster Bridge
Road, London, UK
e-mail: alexander.cohen@kcl.ac.uk

S. Pan · W. Byon · B. S. Ilyas · T. C. Lee
Pfizer, New York, USA

VTE or VTE-related death **Major bleeding** **Major or CRNM bleeding**

Fig. 1 Recurrent VTE or VTE-related death, major bleeding, and composite of major or CRNM bleeding during the treatment period by body weight category. *CI*

confidence interval, *CRNM* clinically relevant non-major, *NE* not estimable, *RR* relative risk, *VTE* venous thromboembolism

Open Access. This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and

indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you

will need to obtain permission directly from the copyright holder. To view a copy of this licence,

visit <http://creativecommons.org/licenses/by-nc/4.0/>.